USP Class VI vs ISO 10993: What Device Teams Actually Need
USP Class VI is a material screen. ISO 10993 is a device-level biological evaluation. Confusing the two is one of the most common causes of late-stage regulatory surprises.
Key takeaways
- USP Class VI tests a material. ISO 10993 evaluates a finished device in its final, sterilized form.
- A USP Class VI certificate on a resin does not make your device biocompatible — it is supporting evidence, not a conclusion.
- ISO 10993-1 drives a risk-based evaluation plan based on contact type and duration, not a fixed test checklist.
- Processing, colorants, mold release, and sterilization can all introduce extractables the resin datasheet never covered.
- Request the documentation set early; grade-level data is far easier to obtain before you have committed to tooling.
What is the actual difference between USP Class VI and ISO 10993?
USP Class VI is a plastics screening protocol. It subjects material extracts to a defined set of in-vivo tests and, if the material passes, the producer can state that the grade meets Class VI criteria. It is a property of the material as tested.
ISO 10993 is a framework for evaluating the biological safety of a finished medical device. It considers the device in the form a patient actually encounters — molded, assembled, colored, sterilized, and packaged. The unit of evaluation is the device, not the pellet.
That distinction is where teams get into trouble. A resin can be fully Class VI compliant while the finished part fails a cytotoxicity screen because of a colorant, a mold release agent, or a sterilization by-product.
Does a USP Class VI resin mean my device is biocompatible?
No. It means the base material passed a material-level screen, which is genuinely useful supporting evidence and a reasonable filter when narrowing a candidate list. It is not a substitute for a device-level biological evaluation.
Treat Class VI as a gate for material selection and ISO 10993 as the obligation you still owe on the finished device. Regulators evaluate the device.
- Class VI narrows your candidate resin list quickly.
- ISO 10993-1 defines the evaluation plan for the finished device.
- Additives and colorants can change the outcome entirely.
- Sterilization can create extractables that did not exist pre-process.
How does contact type change what I have to test?
ISO 10993-1 is risk-based rather than prescriptive. The evaluation scales with how the device contacts the body and for how long, so a surface-contact device with limited exposure carries a very different burden than an implant with permanent tissue contact.
Map your device against contact category and duration first, then build the evaluation plan. Starting from a generic test list either over-tests and wastes budget or under-tests and creates a submission gap.
- Surface contact: skin, mucosal membrane, or breached surface.
- External communicating: blood path, tissue, or bone contact.
- Implant: tissue, bone, or blood contact for extended periods.
- Duration tiers: limited, prolonged, and permanent contact.
What documentation should I request from a distributor?
Ask for grade-specific documentation rather than family-level marketing claims. The useful package includes USP Class VI test reports, ISO 10993 data where the producer has generated it, a Drug Master File reference when the part contacts a drug product, and regulatory change-notification commitments so you learn about formulation changes before they reach your line.
Change notification matters more than teams expect. An undisclosed additive change in a qualified grade can invalidate your biological evaluation and force requalification, so get the commitment in writing during sourcing.
- USP Class VI reports for the exact grade and color.
- ISO 10993 data the producer has already generated.
- DMF or Device Master File reference numbers.
- Formulation change-notification commitments in writing.
Frequently asked questions
- Is USP Class VI required for medical devices?
- It is not a regulatory requirement in itself. It is a widely used material screening standard that provides supporting evidence. Your regulatory obligation is a device-level biological evaluation under ISO 10993-1.
- Can a colorant affect biocompatibility?
- Yes. Pigments, masterbatches, and processing aids all introduce potential extractables. Biological evaluation should be performed on the finished part in its final color and sterilized condition.
- What is a Drug Master File and when do I need one?
- A DMF is confidential documentation a producer files with a regulator covering a material's composition and manufacturing. It matters most when your component contacts a drug product, such as a prefilled syringe or container closure.
- Do I need to retest if the producer changes the formulation?
- Very likely. Any change in additives, stabilizers, or colorants can alter the extractables profile. This is exactly why formulation change-notification commitments should be secured during sourcing.
Ready to specify a grade?
Describe your application and our AI advisor will recommend candidate grades you can sample.